Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts

Detalhes bibliográficos
Autor(a) principal: Esteves, Sofia
Data de Publicação: 2017
Outros Autores: Silva, Sara Carina Duarte, Maciel, P.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/51513
Resumo: Polyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding region of specific genes. This leads to the production of pathogenic proteins containing critically expanded tracts of glutamines. Although polyQ diseases are individually rare, the fact that these nine diseases are irreversibly progressive over 10 to 30 years, severely impairing and ultimately fatal, usually implicating the full-time patient support by a caregiver for long time periods, makes their economic and social impact quite significant. This has led several researchers worldwide to investigate the pathogenic mechanism(s) and therapeutic strategies for polyQ diseases. Although research in the field has grown notably in the last decades, we are still far from having an effective treatment to offer patients, and the decision of which compounds should be translated to the clinics may be very challenging. In this review, we provide a comprehensive and critical overview of the most recent drug discovery efforts in the field of polyQ diseases, including the most relevant findings emerging from two different types of approaches-hypothesis-based candidate molecule testing and hypothesis-free unbiased drug screenings. We hereby summarize and reflect on the preclinical studies as well as all the clinical trials performed to date, aiming to provide a useful framework for increasingly successful future drug discovery and development efforts.
id RCAP_90e44b5f5971377c01001f09b7b99186
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/51513
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Effortspolyglutamine diseasestherapeutic strategiespreclinical trialsclinical trialsCiências Médicas::Medicina ClínicaScience & TechnologyPolyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding region of specific genes. This leads to the production of pathogenic proteins containing critically expanded tracts of glutamines. Although polyQ diseases are individually rare, the fact that these nine diseases are irreversibly progressive over 10 to 30 years, severely impairing and ultimately fatal, usually implicating the full-time patient support by a caregiver for long time periods, makes their economic and social impact quite significant. This has led several researchers worldwide to investigate the pathogenic mechanism(s) and therapeutic strategies for polyQ diseases. Although research in the field has grown notably in the last decades, we are still far from having an effective treatment to offer patients, and the decision of which compounds should be translated to the clinics may be very challenging. In this review, we provide a comprehensive and critical overview of the most recent drug discovery efforts in the field of polyQ diseases, including the most relevant findings emerging from two different types of approaches-hypothesis-based candidate molecule testing and hypothesis-free unbiased drug screenings. We hereby summarize and reflect on the preclinical studies as well as all the clinical trials performed to date, aiming to provide a useful framework for increasingly successful future drug discovery and development efforts.Project ON.2 SR&TD Integrated Program (NORTE-07-0124-FEDER-000021), co-funded by North Portugal Regional Operational Program (ON.2-O Novo Norte), under the National Strategic Reference Framework, through the European Regional Development Fund (ERDF) and also supported by Fundação para a Ciência e Tecnologia through the project POCI-01-0145-FEDER-016818 (PTDC/NEU-NMC/3648/2014)info:eu-repo/semantics/publishedVersionWileyUniversidade do MinhoEsteves, SofiaSilva, Sara Carina DuarteMaciel, P.20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/51513engEsteves, S., Duarte‐Silva, S., & Maciel, P. (2017). Discovery of therapeutic approaches for polyglutamine diseases: a summary of recent efforts. Medicinal research reviews, 37(4), 860-9060198-63251098-112810.1002/med.2142527870126http://onlinelibrary.wiley.com/doi/10.1002/med.21425/fullinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:12:48Zoai:repositorium.sdum.uminho.pt:1822/51513Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:04:47.779558Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
title Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
spellingShingle Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
Esteves, Sofia
polyglutamine diseases
therapeutic strategies
preclinical trials
clinical trials
Ciências Médicas::Medicina Clínica
Science & Technology
title_short Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
title_full Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
title_fullStr Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
title_full_unstemmed Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
title_sort Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
author Esteves, Sofia
author_facet Esteves, Sofia
Silva, Sara Carina Duarte
Maciel, P.
author_role author
author2 Silva, Sara Carina Duarte
Maciel, P.
author2_role author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Esteves, Sofia
Silva, Sara Carina Duarte
Maciel, P.
dc.subject.por.fl_str_mv polyglutamine diseases
therapeutic strategies
preclinical trials
clinical trials
Ciências Médicas::Medicina Clínica
Science & Technology
topic polyglutamine diseases
therapeutic strategies
preclinical trials
clinical trials
Ciências Médicas::Medicina Clínica
Science & Technology
description Polyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding region of specific genes. This leads to the production of pathogenic proteins containing critically expanded tracts of glutamines. Although polyQ diseases are individually rare, the fact that these nine diseases are irreversibly progressive over 10 to 30 years, severely impairing and ultimately fatal, usually implicating the full-time patient support by a caregiver for long time periods, makes their economic and social impact quite significant. This has led several researchers worldwide to investigate the pathogenic mechanism(s) and therapeutic strategies for polyQ diseases. Although research in the field has grown notably in the last decades, we are still far from having an effective treatment to offer patients, and the decision of which compounds should be translated to the clinics may be very challenging. In this review, we provide a comprehensive and critical overview of the most recent drug discovery efforts in the field of polyQ diseases, including the most relevant findings emerging from two different types of approaches-hypothesis-based candidate molecule testing and hypothesis-free unbiased drug screenings. We hereby summarize and reflect on the preclinical studies as well as all the clinical trials performed to date, aiming to provide a useful framework for increasingly successful future drug discovery and development efforts.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/51513
url http://hdl.handle.net/1822/51513
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Esteves, S., Duarte‐Silva, S., & Maciel, P. (2017). Discovery of therapeutic approaches for polyglutamine diseases: a summary of recent efforts. Medicinal research reviews, 37(4), 860-906
0198-6325
1098-1128
10.1002/med.21425
27870126
http://onlinelibrary.wiley.com/doi/10.1002/med.21425/full
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132458206101504